)
Scientists from Hyderabad-based biopharmaceutical company, Suven Life Sciences, are presenting pre-clinical and clinical data on the potential drug candidates developed by the company at the Alzheimer’s Association International Conference (AAIC) being held from July 18-23 in Washington DC, USA.
AAIC is the world’s largest conference of its kind, where researchers from over 70 countries are expected to gather to share their latest study results, discoveries Suven has a portfolio of new molecules through four mechanisms of action and neuronal nicotinic acetylcholine receptors for the symptomatic treatment of cognitive impairment in Alzheimer’s disease and also possibly useful in reducing the disease progression, the company said. “Several exciting new results and data presentations from Suven’s portfolio of investigational neuroscience new chemical entities are being presented at the conference,” the company said.
Most of these molecules are in different stages of pre-clinical and clinical studies in the US and other countries and it is expected to take another couple of years to reach to a level where the company could look at out-licensing opportunities from its portfolio of NCEs, said Venkat Jasti, chairman and CEO of Suven Life Sciences recently.
Suven has eleven internationally discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and obesity in addition to other development stages for Alzheimer’s disease and Schizophrenia, company said.
